The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats.
CGEN-856S is a novel Mas agonist. Herein, we examined the effects of this peptide on isoproterenol (ISO)-induced cardiac remodeling and myocardial infarction (MI) injury. We also sought to determine whether CGEN-856S activates the underlying mechanisms related to Mas receptor activation. Heart hyper...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d2e285fefedf48dba9ca087fbd190ae1 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:d2e285fefedf48dba9ca087fbd190ae1 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:d2e285fefedf48dba9ca087fbd190ae12021-11-18T07:55:13ZThe novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats.1932-620310.1371/journal.pone.0057757https://doaj.org/article/d2e285fefedf48dba9ca087fbd190ae12013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23469229/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203CGEN-856S is a novel Mas agonist. Herein, we examined the effects of this peptide on isoproterenol (ISO)-induced cardiac remodeling and myocardial infarction (MI) injury. We also sought to determine whether CGEN-856S activates the underlying mechanisms related to Mas receptor activation. Heart hypertrophy and fibrosis were induced by ISO (2 mg·kg(-1)·day(-1)) in Wistar rats. After a 7-day treatment period with CGEN-856S (90 µg·kg(-1)·day(-1)) or vehicle, the cardiomyocyte diameter was evaluated in left ventricular sections stained with hematoxylin and eosin, and immunofluorescence labeling and quantitative confocal microscopy were used to quantify the deposition of type I and III collagen and fibronectin in the left ventricles. MI was induced by coronary artery ligation, and CGEN-856S (90 µg·kg(-1)·day(-1)) or saline was administered for 14 days. The Langendorff technique was used to evaluate cardiac function, and left ventricular sections were stained with Masson's trichrome dye to quantify the infarct area. Using Chinese hamster ovary cells stably transfected with Mas cDNA, we evaluated whether CGEN-856S alters AKT and endothelial nitric oxide synthase (eNOS) phosphorylation. CGEN-856S reduced the degree of ISO-induced hypertrophy (13.91±0.17 µm vs. 12.41±0.16 µm in the ISO+CGEN-856S group). In addition, the Mas agonist attenuated the ISO-induced increase in collagen I, collagen III, and fibronectin deposition. CGEN-856S markedly attenuated the MI-induced decrease in systolic tension, as well as in +dT/dt and -dT/dt. Furthermore, CGEN-856S administration significantly decreased the infarct area (23.68±2.78% vs. 13.95±4.37% in the MI+CGEN-856S group). These effects likely involved the participation of AKT and NO, as CGEN-856S administration increased the levels of p-AKT and p-eNOS. Thus, our results indicate that CGEN-856S exerts cardioprotective effects on ISO-induced cardiac remodeling and MI-mediated heart failure in rats through a mechanism likely involving the eNOS/AKT pathway.Sílvia Q SavergniniDanielle IanzerMariana B L CarvalhoAnderson J FerreiraGerluza A B SilvaFúlvia D MarquesAntônio Augusto B PelusoMerav BeimanGady CojocaruYossi CohenAlvair P AlmeidaGalit RotmanRobson A S SantosPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 3, p e57757 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Sílvia Q Savergnini Danielle Ianzer Mariana B L Carvalho Anderson J Ferreira Gerluza A B Silva Fúlvia D Marques Antônio Augusto B Peluso Merav Beiman Gady Cojocaru Yossi Cohen Alvair P Almeida Galit Rotman Robson A S Santos The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats. |
| description |
CGEN-856S is a novel Mas agonist. Herein, we examined the effects of this peptide on isoproterenol (ISO)-induced cardiac remodeling and myocardial infarction (MI) injury. We also sought to determine whether CGEN-856S activates the underlying mechanisms related to Mas receptor activation. Heart hypertrophy and fibrosis were induced by ISO (2 mg·kg(-1)·day(-1)) in Wistar rats. After a 7-day treatment period with CGEN-856S (90 µg·kg(-1)·day(-1)) or vehicle, the cardiomyocyte diameter was evaluated in left ventricular sections stained with hematoxylin and eosin, and immunofluorescence labeling and quantitative confocal microscopy were used to quantify the deposition of type I and III collagen and fibronectin in the left ventricles. MI was induced by coronary artery ligation, and CGEN-856S (90 µg·kg(-1)·day(-1)) or saline was administered for 14 days. The Langendorff technique was used to evaluate cardiac function, and left ventricular sections were stained with Masson's trichrome dye to quantify the infarct area. Using Chinese hamster ovary cells stably transfected with Mas cDNA, we evaluated whether CGEN-856S alters AKT and endothelial nitric oxide synthase (eNOS) phosphorylation. CGEN-856S reduced the degree of ISO-induced hypertrophy (13.91±0.17 µm vs. 12.41±0.16 µm in the ISO+CGEN-856S group). In addition, the Mas agonist attenuated the ISO-induced increase in collagen I, collagen III, and fibronectin deposition. CGEN-856S markedly attenuated the MI-induced decrease in systolic tension, as well as in +dT/dt and -dT/dt. Furthermore, CGEN-856S administration significantly decreased the infarct area (23.68±2.78% vs. 13.95±4.37% in the MI+CGEN-856S group). These effects likely involved the participation of AKT and NO, as CGEN-856S administration increased the levels of p-AKT and p-eNOS. Thus, our results indicate that CGEN-856S exerts cardioprotective effects on ISO-induced cardiac remodeling and MI-mediated heart failure in rats through a mechanism likely involving the eNOS/AKT pathway. |
| format |
article |
| author |
Sílvia Q Savergnini Danielle Ianzer Mariana B L Carvalho Anderson J Ferreira Gerluza A B Silva Fúlvia D Marques Antônio Augusto B Peluso Merav Beiman Gady Cojocaru Yossi Cohen Alvair P Almeida Galit Rotman Robson A S Santos |
| author_facet |
Sílvia Q Savergnini Danielle Ianzer Mariana B L Carvalho Anderson J Ferreira Gerluza A B Silva Fúlvia D Marques Antônio Augusto B Peluso Merav Beiman Gady Cojocaru Yossi Cohen Alvair P Almeida Galit Rotman Robson A S Santos |
| author_sort |
Sílvia Q Savergnini |
| title |
The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats. |
| title_short |
The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats. |
| title_full |
The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats. |
| title_fullStr |
The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats. |
| title_full_unstemmed |
The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats. |
| title_sort |
novel mas agonist, cgen-856s, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/d2e285fefedf48dba9ca087fbd190ae1 |
| work_keys_str_mv |
AT silviaqsavergnini thenovelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT danielleianzer thenovelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT marianablcarvalho thenovelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT andersonjferreira thenovelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT gerluzaabsilva thenovelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT fulviadmarques thenovelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT antonioaugustobpeluso thenovelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT meravbeiman thenovelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT gadycojocaru thenovelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT yossicohen thenovelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT alvairpalmeida thenovelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT galitrotman thenovelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT robsonassantos thenovelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT silviaqsavergnini novelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT danielleianzer novelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT marianablcarvalho novelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT andersonjferreira novelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT gerluzaabsilva novelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT fulviadmarques novelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT antonioaugustobpeluso novelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT meravbeiman novelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT gadycojocaru novelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT yossicohen novelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT alvairpalmeida novelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT galitrotman novelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats AT robsonassantos novelmasagonistcgen856sattenuatesisoproterenolinducedcardiacremodelingandmyocardialinfarctioninjuryinrats |
| _version_ |
1718422758648446976 |